J&J deal could separate Actelion into two companies
NEW BRUNSWICK, N.J. — Johnson & Johnson would separate Actelion’s commercialized portfolio from its research and development assets should it acquire the Swiss-based biotechnology company, reported Reuters.
Citing sources familiar with the matter, the news outlet reported this structure would allow J&J to acquire Actelion for approximately $260 per share in cash, while allowing Actelion shareholders to benefit further financially from its research and development pipeline.
The Actelion research and development pipeline would be spun off into its new publicly traded company, sources said.
A deal could be finalized by late January.
J&J and Actelion declined to comment to Reuters.
No comments found